Professor Toby Prevost was appointed to a Chair in Medical Statistics and Clinical Trials at Imperial College London in January 2016, and is the Head of Statistics in the Imperial Clinical Trials Unit.
His research interests fall within the design, evaluation and meta-analysis of trials of public health and clinical interventions, and he is an experienced researcher, with a Scopus citation H-Index of 36.
Prior to moving to Imperial he was Reader and then Professor of Medical Statistics at King's College London, (Inaugural Lecture), where he was the Deputy Director of the Unit for Medical Statistics, Co-lead in Methodology at the NIHR Biomedical Research Centre at Guy's and St Thomas's NHS Trust, and Co-director of the Statistical Consulting Unit at the Trust.
Here he developed clinical trial collaborations principally in ophthalmology, rheumatology, and from early phase to late phase clinical trials, and in the development of adaptive methods in trials.
Previously he worked at the University of Cambridge. Here he developed expertise in statistical consulting with clinical researchers, the application of statistical methods in medical research, and in trials principally of complex interventions applied across the pathway from modifiable lifestyle behaviours through to obesity and to diabetes and other health consequences.
He worked in posts at Cambridge as:
- a Health Survey Statistician (1991-1993) in the nationwide Health And Lifestyle Survey multidisciplinary team;
- a Consulting Medical Statistician (1996-2002) in the Centre for Applied Medical Statistics, collaborating with clinicians in medical research across the University Clinical School at Addenbrooke's Hospital;
- a Unit and Trial Statistician (2000-2002) in General Practice and Primary Care Research Unit in trials within Type 2 diabetes and Cancer with Professors of General Practice: Head of Unit Ann-Louise Kinmonth, Jon Emery, Simon Griffin;
- a Senior Research Scientist (2002-2006) in the Cambridge MRC Biostatistics Unit undertaking Methodological Research with Professor of Biostatistics in cluster randomised trial design with Head of Unit Simon Thompson, and in multivariate meta-analysis for complex interventions with David Spiegelhalter.
- a Senior Medical Statistician, being Group leader for Statistics within the General Practice and Primary Care Modelling group (2002-2009), lead consulting statistician in the Centre for Applied Medical Statistics (2006-2009), and Statistical Co-investigator in clinical trials across public health, primary care and clinical settings.
He studied at the University of Southampton for a BSc in Mathematics with Statistics, MSc in Statistics with Applications in Medicine, and PhD in Social Statistics.
He held an honorary post from 2007 to 2012 with the University College London Department of Pathology, responsible for statistical modelling in collaborative research investigating the potential of cell-cycle biomarkers to predict the development and progression of cancer.
Since 2009 he has held an honorary visiting post at the University of Cambridge in the Department of Public Health and Primary Care, continuing his involvement in complex intervention trials in smoking cessation, physical activity, and medication adherence.
Professor Prevost has been a member of the NIHR Public Health Research funding board since 2014, and was a member of the Royal Statistical Society Primary Health Care committee from 2002 until 2013. He was a member of the NICE Public Health Interventions Advisory Committee (2008-2013), and since 2013 the NICE Public Health Advisory Committee. In 2017 he was appointed as Expert advisor for the NICE Centre for Guidelines.
Statistical Methods for handling partially missing information
Joana Vasconcelos, PhD in Medical Statistics (2014-), Handling missing statistics in meta-analyses of trials. External supervisor: Rebecca Turner.
Fowzia Ibrahim, PhD in Medical Statistics (2013-), Handling missing data in composite outcomes in Rheumatology Trials. External supervisor: Brian Tom.
The use of Electronic Records in trials
Sena Jawad, PhD in Medical Statistics (2017-), Exploring the Use of Electronic Patient Record Data for Clinical Trials (E-PReDicT). Lead supervisor: Chris Gale
Helen Booth, PhD in Epidemiology (2011-2014), KCL. An Epidemiological study of obesity using primary care electronic health records. Lead supervisor: Martin Gulliford.
Methodology in Complex Intervention Research
Neil Casey, PhD in Medical Statistics (2008-2011). Causal mediation methods in trials of complex interventions. Supervised with Simon Thompson.
Casey N, Thompson SG, Prevost AT. Modelling multiple outcomes to improve the detection of causal mediation effects in complex intervention trials. Trials 2011, 12(Suppl 1):A146
Hardeman W, Prevost AT, Parker RA, Sutton S. Constructing multiplicative measures of beliefs in the theory of planned behaviour. Br J Health Psychol. 2013;18:122-138
Lancaster GA, Campbell MJ, Eldridge S, Farrin A, Marchant M, Muller S, Perera R, Peters TJ, Prevost AT, Rait G. Trials in Primary Care: statistical issues in the design, conduct and evaluation of complex interventions. Statistical Methods in Medical Research 2010;19:349-77
Hardeman W, Michie S, Fanshawe T, Prevost AT, Mcloughlin K, Kinmonth AL. Fidelity of delivery of a physical activity intervention: Predictors and consequences. Psychology and Health 2008;23:11-24
Michie S, Hardeman W, Fanshawe T, Prevost AT, Taylor L, Kinmonth AL. Investigating theoretical explanations for behaviour change: The case study of ProActive. Psychology and Health 2008;23:25-39
Fanshawe TR, Prevost AT, Roberts JS, Green RC, Armstrong D, Marteau TM. Explaining behaviour change after genetic testing: the problem of collinearity between test results and risk estimates. Genetic Testing 2008;12:381-6
Mason D, Prevost AT, Sutton S. Perceptions of absolute versus relative differences between personal and comparison health risk. Health Psychology. 2008;27:87-92
Prevost AT, Mason D, Griffin S, Kinmonth AL, Sutton S, Spiegelhalter D. Allowing for correlations between correlations in random-effects meta-analysis of correlation matrices. Psychological Methods 2007;12:434-50
Turner RM, Prevost AT, Thompson SG. Allowing for imprecision of the intracluster correlation coefficient in the design of cluster randomised trials. Statistics in Medicine 2004;23:1195-1214
Prevost AT. A journey from statistical consultation to funded adaptive trial. Trials 2017;41-42
Statistical Co-investigator: 2016-2021 "TRIBUTE" (Current Phase I/II Adaptive Dose Escalation Randomised Crossover Design Trial Grant): Targeted Regulatory T Cell Therapy for Inflammatory Bowel Disease. PI: G.Lord (KCL) MRC MR/N006445/1 £3.2M
Robertson D, Prevost AT, Bowden J. Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis driven selection rules. Statistics in Medicine 2016 Sep 30;35(22):3907-22.
Robertson D, Prevost AT, Bowden J. Accounting for selection and correlation in the analysis of two-stage genome-wide association studies. Biostatistics 2016;1-16
Robertson D, Prevost AT, Bowden J. Correcting for bias in the selection and validation of informative diagnostic tests. Statistics in Medicine 2015;34:1417-37
David Robertson, PhD in Medical Statistics (2013-2016), Adaptive Design in two-stage studies. Lead supervisor: Jack Bowden.
Prevost AT, Bowden J. Designing a preliminary adaptive study to inform a biomarker trial in Psoriasis. Trials 2011;12(Suppl1),p.A17
2017-2021 Statistical Co-investigator: Increasing eye research capacity and capabilities to tackle the burden of blindness in India: an interdisciplinary collaborative research-based approach between the United Kingdom and India. PI: Sobha Sivaprasad (Moorfields), Imperial Co-investigator Azeem Majeed. RCUK Global Challenge Research Fund: MRC £4M.
The Clarity Trial for Proliferative Diabetic Retinopathy:
Sivaprasad S, Prevost AT, Vasconcelos JC, Riddell A, Murphy C, Kelly J, Bainbridge J, Tudor-Edwards R, Hopkins D, Hykin P. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. The Lancet 2017;389:2193-2203.
Sivaprasad S, Prevost AT, Vasconcelos J, Riddell A, Hykin P. Intravitreal aflibercept for proliferative diabetic retinopathy - Authors' reply.
The Lancet. 2017;390:2141-2142.
2014-2017 Statistical Co-investigator: CLARITY: Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy. PI: Sobha Sivaprasad (Moorfields). MRC/NIHR EME 12/66/15 £1.2M
The Cleopatra Trial for Diabetic Macular Oedema:
Sivaprasad S, Arden G, Prevost AT, Crosby-Nwaobi R, Holmes H, Kelly J, Murphy C, Rubin G, Vasconcelos J, Hykin P. A multicentre phase III randomised controlled single-masked clinical trial evaluating the clinical efficacy and safety of light-masks at preventing dark-adaptation in the treatment of early diabetic macular oedema (CLEOPATRA): study protocol for a randomised controlled trial. Trials 2014;15(1):458
2014-2017 Statistical Co-investigator: CLEOPATRA: A multicentre phase III randomised controlled single masked clinical trial to test the clinical efficacy of LightMasks at preventing dark adaptation in the treatment of early diabetic macular oedema. PI: Sobha Sivaprasad (Moorfields). MRC/NIHR EME 11/30/02 £1.1M
The LEAVO trial for Macular Oedema from Central Retinal Vein Occlusion:
2014-2019 Statistical Co-investigator: LEAVO: A multicentre double-masked randomised non-inferiority clinical trial comparing the clinical and cost effectiveness of intravitreal ranibizumab (Lucentis), aflibercept (Eylea)and bevacizumab (Avastin) for Macular Oedema due to Central Retinal Vein Occlusion. PI: Phil Hykin (Moorfields). NIHR HTA 11/92/03 £2.3M
Hykin P, Sivaprasad S, Prevost AT, Vasconcelos J, Murphy C, Kelly J, Brazier JE, Basarir H, Harding S, Yang Y, Chakravarthy U, Lotery A. Protocol 14PRT/06545:A Multicentre Phase 3 Double-masked Randomised Controlled Non-Inferiority Trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema due to Central Retinal Vein Occlusion (LEAVO trial). The Lancet, 2017.
Other intervention research in Ophthalmology:
Ramu J, Yang Y, Menon G, Bailey C, Narendran N, Bunce C, Quartilho A, Prevost AT, Hykin P, Sivaprasad S. A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study). Eye (Lond) 2015;29(12):1603-12
Jackson TL, Nicod E, Angelis A, Grimaccia F, Prevost AT, Simpson ARH, Kanavos P. Vitreous attachment in age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: a systematic review and meta-analysis. Retina 2013;33:1099-1108
Ophthalmology Trial Data Monitoring Committee roles:
2016-2019 DMC Chair of NIHR EME VICI Trial (Southampton): PI: Andrew Lotery. Eplerenone for central serous chorio-retinopathy.
2012-2014 DMC Member of Trial (Moorfields): PI: Phil Hykin. A Prospective RCT of Intravitreal Ozurdex and Macular Laser Therapy versus Macular Laser Therapy only in Diabetic Macular Oedema
Body Weight Research
2018-2021 Statistical Co-investigator: Increase colonic propionate as a method of preventing weight gain in young adults. PI: Professor Gary Frost (Imperial College London). MRC/NIHR EME 15/185/16
Booth HP, Prevost AT, Gulliford MC. Access to weight reduction interventions for overweight and obese patients in UK primary care: population-based cohort study. BMJ Open. 2015;5(1):e006642
Fildes A, Charlton J, Rudisill C, Littlejohns P, Prevost AT, Gulliford MC. Probability of an Obese Person Attaining Normal Body Weight: Cohort Study Using Electronic Health Records. Am J Public Health. 2015;105(9):e54-9
Booth HP, Prevost AT, Wright AJ, Gulliford MC. Effectiveness of behavioural weight loss interventions delivered in a primary care setting: a systematic review and meta-analysis. Family Practice. 2014;31(6):643-53
2015-2018 TSC member of Cambridge Weight Plan Ltd (UK) funded (Oxford) DROPLET Trial. PI: S.Jebb. Doctor Referral of Overweight People to Low Energy Treatment.
2017-2019 Statistical Co-investigator: Defining ARDS and sepsis sub-phenotypes: a re-analysis of two trials to inform stratified medicine approach with future trials. PI: Manu Shankar-Hari (KCL), Imperial Co-investigator Tony Gordon. MRC/NIHR EME 16/33/01
Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JAH, Herbert J, Chatterjee VKK. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. Journal of Clinical Endocrinology and Metabolism 2000;12:4650-6
Julia Kenkre, NIHR Doctoral Research Fellowship (2017-), Who will benefit from bariatric surgery for diabetes? Using genetic markers and measurement of fat distribution to predict remission of diabetes, lead supervisor - Trisha Tan
Gulliford MC, Charlton J, Booth HP, Fildes A, Khan O, Reddy M, Ashworth M, Littlejohns P, Prevost AT, Rudisill C. Costs and outcomes of increasing access to bariatric surgery for obesity: cohort study and cost-effectiveness analysis using electronic health records. Value in Health 2017;20:85-92
2013-2015 Statistical Co-investigator: Cost-effectiveness of different levels of uptake of bariatric surgery in a large population: Cohort Study and Markov Model. PI: M.Gulliford (KCL). NIHR HS&DR £350k.
Gulliford MC, Booth HP, Reddy M, Charlton J, Fildes A, Prevost AT, Khan O. Effect of Contemporary Bariatric Surgical Procedures on Type 2 Diabetes Remission. A Population-Based Matched Cohort Study. Obesity Surgery 2016; 26:2308-15
Booth HP, Khan O, Fildes A, Prevost AT, Reddy M, Charlton J, Gulliford MC. Changing Epidemiology of Bariatric Surgery in the UK: Cohort Study Using Primary Care Electronic Health Records. Obesity Surgery 2016; 26:1900-5
Booth H, Khan O, Prevost AT, Reddy M, Charlton J, Gulliford MC. Impact of bariatric surgery on clinical depression. Interrupted time series study with matched controls. Journal of Affective Disorders 2015;174:644-9.
Booth H, Khan O, Prevost T, Reddy M, Dregan A, Charlton J, Ashworth M, Rudisill C, Littlejohns P, Gulliford MC. Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study. Lancet Diabetes Endocrinol. 2014;2:963-8.
Development and Validation of Prediction Models
Emery JD, Reid G, Prevost AT, Ravine D, Walter FM. Development and validation of a family history screening questionnaire in Australian primary care. Ann Fam Med. 2014;12:241-9
Walter FM, Prevost AT, Birt L, Grehan N, Restarick K, Morris HC, Sutton S, Rose P, Downing S, Emery JD. Development and evaluation of a brief self-completed family history screening tool for common chronic disease prevention in primary care. British Journal of General Practice 2013;63:393-400
2008-2011 Statistical Co-investigator: Development and validation of a short family history screening tool for chronic disease prevention in primary care. PI: Fiona Walter (Cambridge). NIHR RfPB £220k.
Walter FM, Prevost AT, Vasconcelos J, Hall PN, Burrows NP, Morris HC, Kinmonth AL, Emery JD. Using the seven-point checklist as a diagnostic aid for pigmented skin lesions in general practice: a diagnostic validation study. British Journal of General Practice 2013;63:345-53
Stevenson JM, Williams JL, Burnham TG, Prevost AT, Schiff R, Erskine SD, Davies JG. Predicting adverse drug reactions in older adults; a systematic review of the risk prediction models. Clin Interv Aging. 2014;9:1581-93.
Complex Interventions in End of Life Care
2016-2018 TSC Member of NIHR HTA ImproveCare Trial (KCL). PI: Jonathan Koffman. Management of clinical uncertainty in end of life care
Farquhar M, Prevost AT, McCrone P, Brafman-Price B, Bentley A, Higginson IJ, Todd C, Booth S. The clinical and cost-effectiveness of a Breathlessness Intervention Service for patients with advanced non-malignant disease and their informal carers - mixed findings of a mixed method randomised controlled trial. Trials 2016;17:185.
Farquhar MC, Prevost AT, McCrone P, Brafman-Price B, Bentley A, Higginson IJ, Todd C, Booth S. Is a specialist breathlessness service more effective and cost-effective for patients with advanced cancer and their carers than standard care? Findings of a mixed-method randomised controlled trial. BMC Medicine 2014;12:194
Primary Care Research
2016-present TSC Member of NIHR PGfAR STREAM Trial (Southampton): PI: P.Little. Screen and TREAt for Malnutrition Programme
2015-2017 DMC Chair of BHF and Stroke Association PROPS Trial: PI:J.Mant Preventative Role Of Polypill (in) Stroke: A multi-centre randomised controlled trial of a polypill strategy versus standard primary care for secondary prevention of stroke
2017-present DMC Chair of NIHR HTA REST Trial (Bristol): PI A.Hay. Runny Ear Study.
2014-2018 DMC Chair of NIHR HTA CEDAR Trial (Bristol): PI A.Hay. Children’s drops for ear pain in acute otitis media.
2012-2015 TSC Member of NIHR School for Primary Care OSAC Trial (Bristol): PI: A.Hay. The Oral Steroids for Acute Cough Trial.
2012-2014 Programme Steering Committee Member of EC FP7 POETIC (Cardiff) PI: C.Butler. Point Of carE Testing for urinary tract Infection in primary Care.
2015-2018 Statistical Co-investigator: REDUCE: Electronically-delivered, multi-component interventions to reduce unnecessary antibiotic prescribing in primary care. A cluster randomised trial using electronic health records. PI: M.Gulliford (KCL). NIHR HTA 13/88/10 £533k.
Juszczyk D, Charlton J, McDermott L, Soames J, Sultana K, Ashworth M, Fox R, Hay AD, Little P, Moore MV, Yardley L, Prevost AT, Gulliford MC. Electronically delivered, multicomponent intervention to reduce unnecessary antibiotic prescribing for respiratory infections in primary care: a cluster randomised trial using electronic health records-REDUCE Trial study original protocol. BMJ Open 2016 Aug 4;6(8):e010892
2001-2005 Statistical Co-Investigator: Computer decision support for management of familial cancer in primary care: pilot trial and development of a measure of informed choice in familial cancer. PI: J.Emery (Cambridge). CRUK £148k.
Walter FM, Morris HC, Humphrys E, Hall PN, Prevost AT, Burrows N, Bradshaw L, Wilson EC, Norris P, Walls J, Johnson M, Kinmonth AL, Emery JD. Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. BMJ 2012;345:e4110
Emery J, Morris H, Goodchild R, Fanshawe T, Prevost AT, Bobrow M, Kinmonth AL. The GRAIDS Trial: a cluster randomised controlled trial of computer decision support for the management of familial cancer risk in primary care. British Journal of Cancer 2007;97:486-93
Brown PJB, Warmington V, Laurence M, Prevost AT. Randomised crossover trial comparing the performance of Clinical Terms Version 3 and Read Codes 5 byte set coding schemes in general practice. BMJ 2003;326:1127-30
Robinson SM, Mackenzie-Ross S, Campbell-Hewson GL, Egleston CV, Prevost AT. Psychological effect of witnessed resuscitation on bereaved relatives. The Lancet 1998;352:614-7
Lifestyle Behaviours Research
2011-2016 Statistical Co-investigator: VBI: Development and evaluation of very brief interventions to increase physical activity in primary care. PI: S.Sutton (Cambridge). NIHR PGfAR £1.7M.
Pears S, Bijker M, Morton K, Vasconcelos J, Parker RA, Westgate K, Brage S, Wilson E, Prevost AT, Kinmonth AL, Griffin S, Sutton S, Hardeman W. (VBI) A randomised controlled trial of three very brief interventions for physical activity in primary care. BMC Public Health 2016;16:1033
Mitchell J, Hardeman W, Pears S, Vasconcelos JC, Prevost AT, Wilson E, Sutton S. Effectiveness and cost-effectiveness of a very brief physical activity intervention delivered in NHS Health Checks (VBI Trial): study protocol for a randomised controlled trial. Trials 2016; Jun;17:303
Barakat A, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ, Simmons RK. Changes in physical activity and modelled cardiovascular risk following diagnosis of diabetes: 1-year results from the ADDITION-Cambridge trial cohort. Diabet Med. 2013;30:233-8
Kinmonth AL, Wareham NJ, Hardeman W, Sutton S, Prevost AT, Fanshawe T, Williams K, Ekelund U, Spiegelhalter D, Griffin SJ. Efficacy of a theory-based behavioural intervention to increase physical activity in an at-risk group in primary care (ProActive UK): a randomised trial. The Lancet 2008;371:41-48
2016-2019 Statistical Co-investigator: iQUIT: Improving quit rates among smokers in primary care: Pragmatic trial of effectiveness and cost-effectiveness of a tailored web- and text message-based intervention for smoking cessation. PI S.Sutton (Cambridge) CRUK C1345/A20005 £412k
Naughton F, Jamison J, Boase S, Sloan M, Gilbert H, Prevost AT, Mason D, Smith S, Brimicombe J, Evans R, Sutton S. Randomized controlled trial to assess the short-term effectiveness of tailored web- and text-based facilitation of smoking cessation in primary care (IQUIT). Addiction 2014;109:1184-93
2017-2018 Statistical Co-investigator: Smoking cessation advice in primary care; what does it comprise of and does it make a difference (IQUIT)? PI: Felix Naughton (UEA) CRUK TAG £38k
Naughton F, Prevost AT, Gilbert H, Sutton S. Randomized controlled trial evaluation of a tailored leaflet and SMS text message self-help intervention for pregnant smokers (MiQuit). Nicotine Tob Res. 2012;14:569-77
Naughton F, Prevost AT, Sutton S. Self-help smoking cessation interventions in pregnancy - a systematic review and meta-analysis. Addiction 2008;103:566-79
2011-2014 TSC Member of NIHR HTA START2QUIT Trial (London UCL): PI: H.Gilbert. Randomised trial to increase the uptake of smoking cessation services using Personal Targeted risk information and Taster Sessions
Hollands GJ, Whitwell SC, Parker RA, Prescott NJ, Forbes A, Sanderson J, Mathew CG, Lewis CM, Watts S, Sutton S, Armstrong D, Kinmonth AL, Prevost AT, Marteau TM. Effect of communicating DNA based risk assessments for Crohn's disease on smoking cessation: randomised controlled trial. BMJ 2012;345:e4708
Marteau TM, Aveyard P, Munafò MR, Prevost AT, Hollands GJ, Armstrong D, Sutton S, Hill C, Johnstone E, Kinmonth AL. Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: a randomised controlled trial. PLoS One. 2012;7(4):e35249
2006-2010 Statistical Co-investigator: Risk Communication in Preventive medicine: optimising the impact of DNA risk information. PI: T.Marteau (KCL). MRC £879k.
2017-2022 Statistical Co-investigator: Scalable low-cost interventions to support medication adherence in people prescribed treatment for hypertension in primary care. PI: Stephen Sutton (Cambridge) NIHR PGfAR £2M
2017-2019 Statistical Co-investigator: A novel smartphone app for increasing medication adherence in patients prescribed antihypertensive medication in a community pharmacy setting: Randomised feasibility study. PI: Stephen Sutton (Cambridge) NIHR RfPB £238k
2016-2019 Statistical Co-investigator: MAPS: Feasibility of “Medication Adherence for Patient Support”: A highly tailored text and voice messaging intervention to support medication adherence among patients with Type 2 Diabetes and/or hypertension in primary care. PI: Stephen Sutton (Cambridge) NIHR RfPB £235k
2014-2018 DMC Member of NIHR HTA SUPA Trial (London UCL): PI: R.Horne. Supporting Uptake and Adherence to antiretroviral therapy
Sutton S, Kinmonth AL, Hardeman W, Hughes D, Boase S, Prevost AT, Kellar I, Graffy J, Griffin S, Farmer A. Does Electronic Monitoring Influence Adherence to Medication? Randomized Controlled Trial of Measurement Reactivity. Ann Behav Med. 2014;48(3):293-9.
Farmer A, Hardeman W, Hughes D, Prevost AT, Kim Y, Craven A, Oke J, Boase S, Selwood M, Kellar I, Graffy J, Griffin S, Sutton S, Kinmonth AL. An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes. BMC Fam Pract. 2012;13:30
2006-2008 Statistical Co-investigator: An innovative two-component intervention to support adherence to hypo-glycaemic medication in people with type 2 diabetes: a proof of concept trial. A.Farmer (Oxford), A-L.Kinmonth (Cambridge). MRC £195k.
Savory LA, Griffin SJ, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Simmons RK. Changes in diet, cardiovascular risk factors and modelled cardiovascular risk following diagnosis of diabetes: one-year results from the ADDITION-Cambridge trial cohort. Diabetic Medicine 2014;31:148-55
Bhattarai N, Prevost AT, Wright AJ, Charlton J, Rudisill C, Gulliford MC. Effectiveness of interventions to promote healthy diet in primary care: systematic review and meta-analysis of randomised controlled trials. BMC Public Health 2013;13:1203
Cox BD, Whichelow MJ, Prevost AT. Seasonal consumption of salad vegetables and fresh fruit in relation to the development of cardiovascular disease and cancer. Public Health Nutrition 2000;3:19-29
Williams DEM, Prevost AT, Whichelow MJ, Cox BD, Day NE, Wareham NJ. A cross-sectional study of dietary patterns with glucose intolerance and other features of the metabolic syndrome. British Journal of Nutrition 2000;83:257-66
Prevost AT, Whichelow MJ, Cox BD. Longitudinal dietary changes between 1984-5 and 1991-2 in British adults: associations with socio-demographic, lifestyle and health factors. British Journal of Nutrition 1997;78:873-88
Whichelow MJ, Prevost AT. Dietary patterns and their association with demographic, lifestyle and health parameters in a random sample of British adults. British Journal of Nutrition 1996;76:17-30
Hollands GJ, French DP, Griffin SJ, Prevost AT, Sutton S, King S, Marteau TM. The impact of communicating genetic risks of disease on risk reducing health behaviour: systematic review with meta-analysis. BMJ 2016;352i1102
2011-2014 TSC Member of NIHR PHR AFLY5 Trial TSC (Bristol): PI: D.Lawlor. A cluster RCT of a primary school-based intervention to increase physical activity, decrease sedentary behaviour and improve diet.
Hankonen N, Sutton S, Prevost AT, Simmons RK, Griffin SJ, Kinmonth AL, Hardeman W. Which Behavior Change Techniques are Associated with Changes in Physical Activity, Diet and Body Mass Index in People with Recently Diagnosed Diabetes? Ann Behav Med. 2015;49:7-17
Griffin SJ, Simmons RK, Prevost AT, Williams KM, Hardeman W, Sutton S, Brage S, Ekelund U, Parker RA, Wareham NJ, Kinmonth AL; on behalf of the ADDITION-Plus study team. Multiple behaviour change intervention and outcomes in recently diagnosed type 2 diabetes: the ADDITION-Plus randomised controlled trial. Diabetologia. 2014;57:1308-19
Marteau TM, French DP, Griffin SJ, Prevost AT, Sutton S, Watkinson C, Attwood S, Hollands GJ. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. Cochrane Database of Systematic Reviews 2010 Issue 10. Art. No.: CD007275
Type 2 Diabetes Screening Research
Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ . Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. The Lancet 2012;380(9855):1741-8
Marteau TM, Mann E, Prevost AT, Vasconcelos JC, Kellar I, Sanderson S, Parker M, Griffin S, Sutton S, Kinmonth AL. Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION): a randomised trial. BMJ 2010;340:c2138
2006-2008 Statistical Co-investigator: Didactic versus informed choice invitations to screening: balancing public health benefits and individual choice. PI: T.Marteau (KCL). Wellcome Trust £225k.
Paddison CAM, Eborall HC, Sutton S, French DP, Vasconcelos J, Prevost AT, Kinmonth AL, Griffin SJ. Are people with negative diabetes screening tests falsely reassured? A parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2009;339:b4535
Park P, Simmons RK, Prevost T, Griffin S. Screening for type 2 diabetes is feasible, acceptable, but associated with increased short-term anxiety: a randomised controlled trial in British general practice. BMC Public Health 2008;8:350
Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S. Psychological Impact of Screening for Type 2 Diabetes: Controlled Trial and Comparative Study Embedded in the ADDITION (Cambridge) Randomised Controlled trial. BMJ 2007;335:486
2004-2007 Statistical Co-investigator: Psychological impact of screening for Type 2 diabetes. PI: S.Sutton (Cambridge). Wellcome Trust £136k.
Diabetes Intervention Research
Simmons D, Prevost AT, Bunn C, Holman D, Parker RA, Cohn S, Donald S, Paddison CA, Ward C, Robins P, Graffy J. Impact of Community Based Peer Support in Type 2 Diabetes: A Cluster Randomised Controlled Trial of Individual and/or Group Approaches. PLoS One. 2015;10(3):e0120277
Simmons D, Cohn S, Bunn C, Birch K, Donald S, Paddison C, Ward C, Robins P, Prevost AT, Graffy J. Testing a peer support intervention for people with type 2 diabetes: a pilot for a randomised controlled trial. BMC Fam Pract. 2013;14:5
2008-2011 (Trial Grant) Can peer support delivered as a group or individual intervention enable people with diabetes and improve their health? (RCT of Peer Support In Type 2 Diabetes in Cambridgeshire. PI: David Simmons (Cambridge) Eli Lilly $800k.
Marcovecchio ML, Woodside J, Jones T, Daneman D, Neil A, Prevost T, Dalton RN, Deanfield J, Dunger D; on behalf of the AdDIT Investigators. Adolescent Type 1 Diabetes cardio-renal Intervention Trial (AdDIT): Urinary screening and baseline biochemical and cardiovascular assessments. Diabetes Care. 2014;37:805-13
Marcovecchio ML, Dunger DB, Dalton RN, Daneman D, Deanfield JE, Gray A, Jones TW, Neil A, Prevost AT; the AdDIT study Writing Group. Adolescent Type 1 Diabetes cardio-renal Intervention Trial (AdDIT): Study Protocol. BMC Pediatrics 2009;9:79
Amin R, Widmer B, Prevost AT, Schwarze P, Cooper J, Edge J, Marcovecchio L, Neil A, Dalton RN, Dunger DB. Risk of Microalbuminuria and progression to Macroalbuminuria in a cohort with childhood onset Type 1 Diabetes: prospective observational study. BMJ 2008;336:697-701
2014-2018 Statistical Co-investigator: APIPPRA: Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept. PI: A.Cope (KCL). Bristol-Myers Squibb £3M.
Kirkham B, Chaabo K, Hall C, Garrood T, Mant T, Allen E, Vincent A, Vasconcelos JC, Prevost AT, Panayi GS, Corrigall VM. Safety and patient response as indicated by biomarker changes to BiP in the Phase I/IIa RAGULA clinical trial in rheumatoid arthritis. Rheumatology 2016 Nov;55(11):1993-2000
Östör AJK, Richards CA, Tytherleigh-Strong G, Bearcroft PW, Prevost AT, Speed CA, Hazleman BL. Validation of clinical examination versus magnetic resonance imaging and arthroscopy for the detection of rotator cuff lesions. Clinical Rheumatology 2013;32:1283-91
D’Vaz AP, Ostor AJK, Speed CA, Jenner JR, Bradley M, Prevost AT, Hazleman BL. Pulsed low-intensity ultrasound therapy for chronic lateral epicondylitis: a randomized controlled trial. Rheumatology 2006;45:566-70
Ostor AJK, Richards CA, Prevost AT, Speed CA, Hazleman BL. Diagnosis and relation to general health of shoulder disorders presenting to primary care. Rheumatology 2005;44:800-5
Ostor AJK, Richards CA, Prevost AT, Hazleman BL, Speed CA. Interrater reproducibility of clinical tests for rotator cuff lesions. Annals of the Rheumatic Diseases 2004;63:1288-92
Cancer Trial Research
Corrie PG, Moody AM, Armstrong G, Nolasco S, Lao-Sirieix S-H, Bavister L, Prevost AT, Parker R, Sabes-Figuera R, McCrone P, Balsdon H, McKinnon K, Hounsell A, O’Sullivan B, Barclay S. Is community treatment best? A randomised trial comparing delivery of cancer treatment in the hospital, home and GP surgery. British Journal of Cancer 2013;109:1549-55
2008-2011 Statistical Co-investigator: OUTREACH: A randomised trial comparing delivery of cancer systemic therapy in three different settings: a patient’s home, a general practice surgery and a hospital day unit. PI: P.Corrie (Cambridge) NIHR RfPB £250k.
Cancer Diagnostic and Prognostic Cell-Cycle Biomarkers
Kelly JD, Dudderidge TJ, Wollenschlaeger A, Okoturo O, Burling K, Tulloch F, Halsall I, Prevost T, Prevost AT, Vasconcelos JC, Robson W, Leung HY, Vasdev N, Pickard RS, Williams GH, Stoeber K. Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of mcm5 and nuclear matrix protein 22. PLoS One. 2012;7:e40305
Kulkarni AA, Kingsbury SR, Tudzarova S, Hong HK, Loddo M, Rashid M, Rodriguez-Acebes S, Prevost AT, Ledermann JA, Stoeber K, Williams GH. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma. Clinical Cancer Research 2009;15:2417-25
Loddo M, Kingsbury SR, Rashid M, Proctor I, Holt C, Young J, El-Sheikh S, Falzon M, Eward KL, Prevost AT, Sainsbury R, Stoeber K, Williams GH. Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. British Journal of Cancer 2009;100:959-70
2004-2008 Statistical Co-investigator: Evaluation of urinary Mcm5 as a diagnostic agent in genito-urinary tract malignancy. PI: G.Williams (London UCL). CRUK £500k
Williams GH, Swinn R, Prevost AT, de Clive-Lowe P, Halsall I, Going JJ, Hales CN, Stoeber K, Middleton SJ. Diagnosis of oesophageal cancer by detection of minichromosome maintenance 5 protein in gastric aspirates. British Journal of Cancer 2004;91:714-9
Stoeber K, Swinn R, Prevost AT, DeClive-Lowe P, Halsall, I, Dilworth SM, Marr, J, Turner WH, Bullock N, Doble A, Hales CN, Williams GH. Diagnosis of genito-urinary tract cancer by detection of Mcm5 in urine sediments. Journal of the National Cancer Institute 2002;94:1071-9
Depression and related psychological health research
2016-present DMC Chair of NIHR HTA TANDEM Trial (London QMuL): PI: S.Taylor. Intervention for anxiety or depression in COPD.
2015-2017 TSC Member of NIHR HTA BEADS Trial (Nottingham/Sheffield). PI S.Thomas. How feasible is a study to investigate the clinical and cost-effectiveness of a psychological intervention for people with post-stroke depression?
2013-2014 DMC Member of NIHR PGfAR EPOS Trial (London QMUL): PI: S.Priebe Patient-clinician communication in community mental health
2009-2012 TSC Member of NIHR HTA FIAT Trial (London QMUL): PI: S.Priebe. Financial incentives to improve adherence to anti-psychotic maintenance medication
Paddison CA, Eborall HC, French DP, Kinmonth AL, Prevost AT, Griffin SJ, Sutton S. Predictors of anxiety and depression among people attending diabetes screening: A prospective cohort study embedded in the ADDITION (Cambridge) Randomised Control Trial. British Journal of Health Psychology 2011;16:213-26
Braithwaite D, Emery J, Walter F, Prevost AT, Sutton S. Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. Journal of the National Cancer Institute 2004;96:122-133
et al., 2017, Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial, Lancet, Vol:389, ISSN:0140-6736, Pages:2193-2203
et al., 2017, Intravitreal aflibercept for proliferative diabetic retinopathy Reply, Lancet, Vol:390, ISSN:0140-6736, Pages:2141-2142
et al., 2017, Costs and Outcomes of Increasing Access to Bariatric Surgery: Cohort Study and Cost-Effectiveness Analysis Using Electronic Health Records, Value in Health, Vol:20, ISSN:1098-3015, Pages:85-92
et al., 2016, A randomised controlled trial of three very brief interventions for physical activity in primary care, Bmc Public Health, Vol:16, ISSN:1471-2458
Robertson DS, Prevost AT, Bowden J, 2016, Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules, Statistics in Medicine, Vol:35, ISSN:0277-6715, Pages:3907-3922